Pioglitazone

Patients with type 2 diabetes uncontrolled by metformin who received pioglitazone and insulin demonstrated increased risk for ischemic heart disease, according to findings published in the Journal of Diabetes and Its Complications.

When she first enrolled as a freshman undergraduate student at West Virginia University, Carmella Evans-Molina, MD, PhD, never imagined she would become an award-winning diabetes researcher.

The Endocrine Society and other organizations recently called on the FDA to lower its limit on the endocrine-disrupting chemical bisphenol A, or BPA, in food contact articles.

Both 15 mg and 30 mg pioglitazone doses have similar efficacy as 45 mg for preventing new-onset diabetes, stroke and myocardial infarction but with lower risk for adverse events, according to study findings.

Pioglitazone was safe and effective in improving liver histology among patients with nonalcoholic steatohepatitis, according to a presenter at the Digital NAFLD Summit 2021.

Eight professional societies issued a joint report on the dangers associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, calling on clinicians to work together across specialties and align treatment strategies.

Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.

Lifestyle or medical therapy in prediabetes to reduce later cardiovascular events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker.

Changes in liver fat can predict changes in steatosis but not other liver histological parameters like improvements in nonalcoholic fatty liver disease activity score or resolution of nonalcoholic steatohepatitis without worsening of fibrosis, according to data published in Journal of Hepatology.

Adults with type 2 diabetes prescribed a combination of insulin and pioglitazone therapy were 50% less likely to die during follow-up when compared with adults prescribed insulin without pioglitazone, with findings driven by a lower risk for noncardiovascular death, according to findings published in The Journal of Clinical Endocrinology & Metabolism.